Business
Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB:...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple MyelomaToronto, Ontario--(Newsfile Corp. - July 13, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"TELO\") is pleased to announce that it has commenced the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma (\"MM\") patients that are at high-risk of developing treatment resistance. This study is the second study being carried out in collaboration with the Mayo Clinic to evaluate the Company's prognostic technology to address multiple unmet clinical needs in MM.MM is a highly challenging and deadly blood cancer that forms in plasma cells, a type of white blood cell. Symptoms include bone pain, frequent infections, fatigue, and weight loss. There are currently several combinations of drugs in clinical use for the treatment of MM and most patients initially respond to treatment and enter remission. However, disease remission is typically followed by treatment resistance and relapse, this can occur from as early as 3 months from initiation of treatment until 24 months. Identifying patients who will develop drug resistance prior to relapse is a critical unmet need in the management of MM. Addressing this unmet need will allow healthcare providers to identify patients at high-risk of drug resistance and modify their treatment regimens accordingly.The identification of patients at high-risk of treatment resistance presents the potential for regular and continuous patient monitoring and consequently, dynamic real-time treatment modification. The incidence rate of MM in the USA is approximately 35,000 cases per year with an estimated potential total addressable market of over 250,000 tests per year.In 2020, TELO entered into a collaboration agreement with the Mayo Clinic to conduct clinical studies targeting the development of two clinical prognostic tests for MM. On July 6, 2022, TELO announced the completion of the processing of clinical samples related to its lead product in development for smouldering multiple myeloma (SMM) and is in the process of data review and analysis. For further clarification, the clinical study being launched for drug resistance, the subject of this press release, is the second prognostic test in development in collaboration with the Mayo Clinic.\"We are excited ...